Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DIAN-TU phase II/III trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease
NL-OMON54843Phase 3Recruiting
- Sponsor
- Washington University in St. Louis
- Start
- Nov 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of gantenerumab, solanezumab in Alzheimer's disease (AD), sponsored by Washington University in St. Louis. Started Nov 2020; status: recruiting.
02
Drugs
gantenerumabsolanezumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON54843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54843.